Recent progress on curcumin-based therapeutics: a patent review (2012-2016). Part I: Curcumin

References

• Evans BE, Rittle KE, Bock MG, DiPardo RM, Freidinger RM, Whitter WL, Lundell GF, Veber DF, Anderson PS, Chang RS, et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem. 1988;31:2235–46.
   PubMed Web of Science ®Google Scholar
• Dixon N, Wong LS, Geerlings TH, Micklefield J. Cellular targets of natural products. Nat Prod Rep. 2007;24:1288–310. Epub 2007/11/23.
   PubMed Web of Science ®Google Scholar
• Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 2012;75:311–35.
   PubMed Web of Science ®Google Scholar
• Harvey AL. Natural products in drug discovery. Drug Discov Today. 2008;13:894–901.
   PubMed Web of Science ®Google Scholar
• Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol Adv. 2014;32:1053–64.
   PubMed Web of Science ®Google Scholar
• Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, Sung B, Tharakan ST, Misra K, Priyadarsini IK, Rajasekharan KN, Aggarwal BB. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol. 2008;76:1590–611. Epub 2008/09/09.
   PubMed Web of Science ®Google Scholar
• Minassi A, Sanchez-Duffhues G, Collado JA, Munoz E, Appendino G. Dissecting the pharmacophore of curcumin. Which structural element is critical for which action? J Nat Prod. 2013;76:1105–12.
   Google Scholar
• Magesh S, Chen Y, Hu L. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev. 2012;32:687–726. Epub 2012/05/03.
   PubMed Web of Science ®Google Scholar
• Chabner BA, Roberts TG, Jr. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5:65–72. Epub 2005/01/05.
   PubMed Web of Science ®Google Scholar
• Sawyers C. Targeted cancer therapy. Nature. 2004;432:294-7. Epub 2004/11/19.
   Google Scholar
• Yang M, Liu P, Huang P. Cancer stem cells, metabolism, and therapeutic significance. Tumour Biol. 2016;37:5735–42.
   PubMed Web of Science ®Google Scholar
• Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008;269:199–225.
   PubMed Web of Science ®Google Scholar
• Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer. 2011;10:12. Epub 2011/02/09.
   Google Scholar
• Chadalapaka G, Jutooru I, Chintharlapalli S, Papineni S, Smith R, 3rd, Li X, Safe S. Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res . 2008;68:5345–54. Epub 2008/07/03.
   PubMed Web of Science ®Google Scholar
• Jutooru I, Chadalapaka G, Lei P, Safe S. Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J Biol Chem. 2010;285:25332–44. Epub 2010/06/12.
   PubMed Web of Science ®Google Scholar
• Langhans SA-B, Lee SJ, inventors; The Nemours Foundation, USA. assignee. Method for identifying therapeutic agents for treatment of cancer patent US20130116335A1. 2013.
   Google Scholar
• Rajkumar T, Gopal G, Selvaluxmi G, Rajalekshmy KR. CDC27 protein is involved in radiation response in squamous cell cervix carcinoma. Indian J Biochem Biophys. 2005;42:271–8. Epub 2005/10/01.
   Google Scholar
• Khan S, Karmokar A, Howells L, Thomas AL, Bayliss R, Gescher A, Brown K. Targeting cancer stem-like cells using dietary-derived agents - Where are we now? Mol Nutr Food Res. 2016;60:1295–309.
   PubMed Web of Science ®Google Scholar
• Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.
   PubMed Web of Science ®Google Scholar
• Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, Cascone T, Diao L, Wang J, Wistuba, II, Heymach JV, Lippman SM, Desgrosellier JS, Anand S, Weis SM, Cheresh DA. An integrin beta(3)-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol. 2014;16:457–68. Epub 2014/04/22.
   PubMed Web of Science ®Google Scholar
• Cheresh DA, Gozo M, Yebra M, Seguin L, inventors; The Regents of the University of California, USA. assignee. Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype patent WO2016100858A1. 2016.
   Google Scholar
• Jamasbi RJ, Almanaa TN, Geusz ME. Cancer stem cell survivor lines. Google Patents; 2015.
   Google Scholar
• Almanaa TN, Geusz ME, Jamasbi RJ. Effects of curcumin on stem-like cells in human esophageal squamous carcinoma cell lines. BMC Complement Altern Med. 2012;12:195. Epub 2012/10/26.
   Web of Science ®Google Scholar
• Srivastava RK, Shankar S, inventors; Glax L.L.C., USA. assignee. Methods of treating and preventing cancer by targeting and inhibiting cancer stem cells patent WO2012159085A2. 2012.
   Google Scholar
• Witta S, inventor; USA. assignee. Cancer treatment composition comprising Wnt signaling pathway inhibitors and histone deacetylase inhibitors histone deacetylase inhibitors patent US20150209391A1. 2015.
   Google Scholar
• Ramasamy TS, Ayob AZ, Myint HH, Thiagarajah S, Amini F. Targeting colorectal cancer stem cells using curcumin and curcumin analogues: insights into the mechanism of the therapeutic efficacy. Cancer Cell Int. 2015;15:96. Epub 2015/10/13.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhang W, Guo Z, Ma F, Wu Y, Bai Y, Gong W, Chen Y, Cheng T, Zhi F, Zhang Y, Wang J, Jiang B. Inhibition of the transcription factor Sp1 suppresses colon cancer stem cell growth and induces apoptosis in vitro and in nude mouse xenografts. Oncol Rep. 2013;30:1782–92. Epub 2013/07/24.
   Google Scholar
• Safe S, Kasiappan R. Natural Products as Mechanism-based Anticancer Agents: Sp Transcription Factors as Targets. Phytother Res. 2016;30:1723–32. Epub 2016/11/05.
   PubMed Web of Science ®Google Scholar
• Chen Z, Han L, Xu M, Xu Y, Qian X. Rationally designed multitarget anticancer agents. Curr Med Chem. 2013;20:1694–714.
   PubMed Web of Science ®Google Scholar
• Bolognesi ML. Polypharmacology in a single drug: multitarget drugs. Curr Med Chem. 2013;20:1639–45.
   PubMed Web of Science ®Google Scholar
• Peters JU. Polypharmacology - foe or friend? J Med Chem. 2013;56:8955–71.
   PubMed Web of Science ®Google Scholar
• Santen RJ, Aiyer SE, inventors; University of Virginia Patent Foundation, USA. assignee. Compositions and methods for treating cancer comprising an immunoconjugate of a monoclonal antibody and a pro-apoptotic drug combined with a second pro-apoptotic drug patent WO2012154809A1. 2012.
   Google Scholar
• Goldmacher VS, Audette CA, Guan Y, Sidhom E-H, Shah JV, Whiteman KR, Kovtun YV. High-Affinity Accumulation of a Maytansinoid in Cells via Weak Tubulin Interaction. Plos One. 2015 Feb 11;10(2):e0117523.
   PubMed Web of Science ®Google Scholar
• Pillow TH, Tien J, Parsons-Reponte KL, Bhakta S, Li H, Staben LR, Li G, Chuh J, Fourie-O'Donohue A, Darwish M, Yip V, Liu L, Leipold DD, Su D, Wu E, Spencer SD, Shen B-Q, Xu K, Kozak KR, Raab H, Vandlen R, Phillips GDL, Scheller RH, Polakis P, Sliwkowski MX, Flygare JA, Junutula JR. Site-Specific Trastuzumab Maytansinoid Antibody-Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering. Journal of Medicinal Chemistry. 2014;57:7890–9.
   Google Scholar
• Pal S, Choudhuri T, Chattopadhyay S, Bhattacharya A, Datta GK, Das T, Sa G. Mechanisms of curcumin-induced apoptosis of Ehrlich's ascites carcinoma cells. Biochemical and Biophysical Research Communications. 2001;288:658–65.
   PubMed Web of Science ®Google Scholar
• Azam M, Kesarwani M, inventors; Children's Hospital Medical Center, USA. assignee. Therapy for leukemia comprising a combination of a c-Fos inhibitor and a Dusp-1 inhibitor and a BCR-ABL tyrosine kinase inhibitor patent US20140031356A1. 2014.
   Google Scholar
• Molina G, Vogt A, Bakan A, Dai WX, de Oliveira PQ, Znosko W, Smithgall TE, Bahar I, Lazo JS, Day BW, Tsang M. Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat Chem Biol. 2009;5:680–7.
   PubMed Web of Science ®Google Scholar
• Barthomeuf C, Chollet P, Planchat E, Cure H, inventors; INSERM Institut National de la Sante et de la Recherche Medicale, Fr.; Centre Jean Perrin; Universite d'Auvergne Clermont I. assignee. Methods and pharmaceutical compositions for the treatment of hormone-refractory prostate cancers patent WO2012146706A1. 2012.
   Google Scholar
• Barthomeuf C, Chollet P, Bayet-Robert M, inventors; INSERM Institut National de la Sante et de la Recherche Medicale, Fr.. assignee. Curcuminoids in combination docetaxel for the treatment of cancer and tumour metastasis patent WO2010115852A1. 2010.
   Google Scholar
• Reynolds B, Deleyrolle L, inventors; University of Florida Research Foundation, Incorporated, USA. assignee. Methods of treating proliferative diseases such as cancer using natural compounds and/or ketogenic diet patent WO2014159500A1. 2014.
   Google Scholar
• Talalay P, Liu H, inventors; The Johns Hopkins University, USA. assignee. Compositions comprising exemestane and novel therapeutic uses thereof patent WO2015009902A1. 2015.
   Google Scholar
• Wu JC, Tsai ML, Lai CS, Wang YJ, Ho CT, Pan MH. Chemopreventative effects of tetrahydrocurcumin on human diseases. Food & Function. 2014;5:12–7.
   PubMed Web of Science ®Google Scholar
• Wright LE, Frye JB, Gorti B, Timmermann BN, Funk JL. Bioactivity of Turmeric-derived Curcuminoids and Related Metabolites in Breast Cancer. Current Pharmaceutical Design. 2013;19:6218–25.
   PubMed Web of Science ®Google Scholar
• Saha S, Welsch D, Decrescenzo G, Roix JJ, inventors; BioMed Valley Discoveries, Inc., USA. assignee. Cancer treatments using combinations of PI3K/AKT pathway and ERK inhibitors patent WO2015095829A1. 2015.
   Google Scholar
• Saha S, Welsch D, Decrescenzo G, Roix JJ, inventors; BioMed Valley Discoveries, Inc., USA. assignee. Cancer treatment using combinations of ERK and RAF kinase inhibitors patent WO2015095819A2. 2015.
   Google Scholar
• Saha S, Welsch D, Decrescenzo G, Roix JJ, inventors; BioMed Valley Discoveries, Inc., USA. assignee. Cancer treatments using ERK1/2 kinase and Bcl-2 proteins inhibitors patent WO2015095834A2. 2015.
   Google Scholar
• Saha S, Welsch D, DeCrescenzo G, Roix JJ, inventors; BioMed Valley Discoveries, Inc., USA. assignee. Cancer treatments using combinations of mTOR and ERK inhibitors patent WO2015095831A1. 2015.
   Google Scholar
• Ahsan H, Hadi SM. Strand scission in DNA induced by curcumin in the presence of Cu(II). Cancer Lett. 1998;124:23–30. Epub 1998/03/21.
   PubMed Web of Science ®Google Scholar
• Mittra I, inventor; Tata Memorial Centre, India. assignee. Plant polyphenol and copper (II) mediated degradation of DNA and RNA patent WO2015011732A2. 2015.
   Google Scholar
• Khan HY, Zubair H, Ullah MF, Ahmad A, Hadi SM. Oral administration of copper to rats leads to increased lymphocyte cellular DNA degradation by dietary polyphenols: implications for a cancer preventive mechanism. Biometals. 2011;24:1169–78. Epub 2011/07/01.
   PubMed Web of Science ®Google Scholar
• Pucci D, Bloise R, Bellusci A, Bernardini S, Ghedini M, Pirillo S, Valentini A, Crispini A. Curcumin and cyclopalladated complexes: a recipe for bifunctional biomaterials. J Inorg Biochem. 2007;101:1013–22.
   PubMed Web of Science ®Google Scholar
• Valentini A, Conforti F, Crispini A, De Martino A, Condello R, Stellitano C, Rotilio G, Ghedini M, Federici G, Bernardini S, Pucci D. Synthesis, oxidant properties, and antitumoral effects of a heteroleptic palladium(II) complex of curcumin on human prostate cancer cells. J Med Chem. 2009;52:484–91.
   PubMed Web of Science ®Google Scholar
• Miklasova N, Miklas R, Devinsky F, inventors; Univerzita Komenskeho v Bratislave, Slovakia; Centrum Vedecko-Technickych Informacii Sr CVTI SR. assignee. Preparation of palladium complexes of curcumin and its analogues as antitumor agent patent WO2014175841A1. 2014.
   Google Scholar
• Naksuriya O, Okonogi S, Schiffelers RM, Hennink WE. Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials. 2014;35:3365–83.
   PubMed Web of Science ®Google Scholar
• Sripathy R, Mandapati VNSRR, Ajay G, Somashekara N, Chaniyilparampu RN, Gokaraju RR, Gokaraju GR, Bhupathiraju K, Anjana D, inventors; Laila Pharmaceuticals Pvt. Ltd., India. assignee. Novel highly bioavailable, water soluble and sustained release nanoformulations hydrophobic plant derived compounds and extracts patent US20150072012A1. 2015.
   Google Scholar
• Schentag JJ, McCourt MP, Mielnicki L, Hughes J, inventors; USA. assignee. Cholestosome vesicles for incorporation of molecules into chylomicrons patent WO2014152795A2. 2014.
   Google Scholar
• Tummala H, Kumar S, inventors; South Dakota Board of Regents, USA. assignee. Curcuminoid complexes with enhanced stability, solubility and/or bioavailability patent US20140271530A1. 2014.
   Google Scholar
• Bansal AK, Dantuluri AKR, Bhaskarao SG, Bapurao PY, inventors; National Institute of Pharmaceutical Education and Research, India. assignee. Nanocrystalline solid dispersion compositions and process of preparation thereof patent WO2013132457A2. 2013.
   Google Scholar
• Gennari G, Panfilo S, inventors; Fidia Farmaceutici S.p.A., Italy. assignee. New pharmaceutical compositions containing phosphatidylserine and curcumin patent WO2013111066A2. 2013.
   Google Scholar
• Ensign L, Cone R, Hanes JS, inventors; The Johns Hopkins University, USA. assignee. Nanoparticle formulations comprising PEG derivatives with enhanced mucosal penetration patent WO2013110028A1. 2013.
   Google Scholar
• Chaniyilparampu RN, Nair AK, Parthasarathy K, Gokaraju GR, Gokaraju RR, Bhupathiraju K, inventors; Laila Pharmaceuticals Pvt. Ltd., India. assignee. Curcuminoids and its metabolites for the application in allergic ocular/nasal conditions patent IN2009CH00646A. 2012.
   Google Scholar
• Friedman JM, Navati MS, Friedman AJ, Nacharaju P, Krausz A, inventors; Albert Einstein College of Medicine, Inc., USA. assignee. Therapeutic nanoparticles and methods thereof patent WO2015195458A1. 2015.
   Google Scholar
• Chaniyilparampu RN, Mungala M, Kapoor A, Gokaraju GR, Gokaraju RR, Kiran B, Golakoti T, Nair AK, Murali MR, Parthasarathy K, inventors; Laila Pharmaceuticals Pvt. Ltd, India. assignee. Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases patent WO2010070675A2. 2010.
   Google Scholar
• Ranjan AP, Mukerjee A, Vishwanatha JK, Helson L, inventors; SignPath Pharma Inc., USA; University of North Texas Health Science Center. assignee. Curcumin-ER, a liposomal-PLGA sustained release nanocurcumin for minimizing QT prolongation for cancer therapy patent US20140065061A1. 2014.
   Google Scholar
• Kumar A, Mohapatra TSS, Cameron D, inventors; University of South Florida, USA. assignee. Nanoparticle targeted drug delivery to the lungs using extra-testicular sertoli cells patent WO2009105278A2. 2009.
   Google Scholar
• Liu K, Lang Y, Xu H, Fan H, Hu D, inventors; Suzhou Leina Pharmaceutical Research and Development Co., Ltd., Peop. Rep. China. assignee. Curcumin micelle medicine carrying system and preparation method thereof patent CN104758255A. 2015.
   Google Scholar
• Senn S, Rachman I, inventors; Immix Corporation, USA. assignee. Cancer therapeutics comprising a micelle construct attached to a glut-1 antibody and an inhibitor of NF-κB patent WO2013138735A1. 2013.
   Google Scholar
• Maitra A, Pramanik D, inventors; The Johns Hopkins University, USA. assignee. Smart polymeric nanoparticles which overcome multidrug resistance to cancer chemotherapeutics and treatment-related systemic toxicity patent WO2012078831A2. 2012.
   Google Scholar
• Dhar S, Marrache SM, inventors; University of Georgia Research Foundation, Inc., USA. assignee. Nanoparticles for mitochondrial trafficking of agents patent WO2013123298A1. 2013.
   Google Scholar
• Lillard JW, inventor; Morehouse School of Medicine, USA. assignee. Delivery system for specifically targeting cancer cells by tumor assocd. antigen binding ligand-coated nanoparticles contg. cytotoxic agent, and method of use thereof patent WO2013025418A1. 2013.
   Google Scholar
• Kar SK, Das G, Suar M, inventors; India. assignee. A pharmaceutical combination of nano curcumin and isoniazide for treating tuberculosis patent WO2014170820A2. 2014.
   Google Scholar
• Kar SK, Akhtar F, Ray G, Pandey AK, inventors; Kar, Santosh, Kumar, India; Pandey, Atul, Kumar. assignee. Curcumin nanoparticles with improved bioavailability and methods of producing the same patent WO2010013224A2. 2010.
   Google Scholar
• Chauhan S, Jaggi M, Yallapu MM, inventors; Sanford Research/USD, USA. assignee. Magnetic nanoparticle formulations, methods for making such formulations, and methods for their use patent WO2012078745A1. 2012.
   Google Scholar
• Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4:807–18. Epub 2007/11/15.
   PubMed Web of Science ®Google Scholar
• Awasthi V, Lagisetty P, Agashe H, inventors; The University of Oklahoma, USA. assignee. Antiproliferative compositions comprising curcumin analogs and methods of producing and using same patent US20120288555A1. 2012.
   Google Scholar